rolipram has been researched along with Bright Disease in 1 studies
Bright Disease: A historical classification which is no longer used. It described acute glomerulonephritis, acute nephritic syndrome, or acute nephritis. Named for Richard Bright.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the effects of rolipram in prevention and delayed treatment of crescentic glomerulonephritis in Wistar Kyoto rats." | 3.70 | Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. ( Agarwal, S; Karkar, AM; Morel, D; Pusey, CD; Smith, J; Tam, FW; Thompson, EM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tam, FW | 1 |
| Smith, J | 1 |
| Agarwal, S | 1 |
| Karkar, AM | 1 |
| Morel, D | 1 |
| Thompson, EM | 1 |
| Pusey, CD | 1 |
1 other study available for rolipram and Bright Disease
| Article | Year |
|---|---|
Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis.
Topics: Animals; Antibodies; Basement Membrane; Disease Models, Animal; Glomerulonephritis; Kidney; Kidney G | 2000 |